Likewise, HDAC inhibitors can render cancer cells more susceptible to chemotherapy, with panobinostat demonstrating efficacy in diminishing resistance to cisplatin in lung cancer cells by influencing HIF-1α. This evidence concerns the gene HDAC9 and cancer.